Has the FDA approved the use of niraparib and abiraterone tablets?

Niraparib Abiraterone Tablets ( Akeega) has been approved by the U.S. Food and Drug Administration (FDA), becoming the first treatment option to combine a PARP inhibitor and abiraterone acetate. This approval marks a major advance in the treatment of prostate cancer, particularly in the treatment of BRCA-positive metastatic castration-resistant prostate cancer (mCRPC).

Niraparib and Abiraterone Acetate combination treatment consists of two active ingredients: niraparib and abiraterone acetate. Niraparib is a PARP inhibitor that accelerates the death of cancer cells by preventing them from repairing DNA damage. Abiraterone acetate further inhibits cancer progression by reducing the synthesis of androgens and inhibiting the stimulation of cancer cells by androgens. Combining these two drugs makes the treatment more effective, especially in those with BRCA gene mutations.

The FDA's approval was based on the positive performance of niraparib and abiraterone tablets in clinical trials, particularly its potential to delay disease progression and improve patient survival. Niraparib and abiraterone are often used together with prednisone, a combination therapy that can further enhance the effectiveness of the treatment. For patients who often develop resistance to traditional treatments, niraparib and abiraterone tablets offer a new treatment option.

It is worth noting that niraparib and abiraterone tablets are only suitable for patients with BRCA mutation-positive, metastatic castration-resistant prostate cancer. Therefore, before starting treatment, patients need to undergo genetic testing to confirm eligibility. The FDA's approval not only brings a new direction to the treatment of prostate cancer, but also provides patients with more personalized treatment options, further improving the accuracy of treatment.

Reference materials:https://www.drugs.com/akeega.html